PDS Biotech Cuts 36% of Workforce and Terminates COO Amid Strategic Refocus
PDSB is trading near its 52-week low of $0.195 (13% above the low).
Summary
PDS Biotech is laying off 36% of its workforce and has terminated COO Stephan Toutain without cause, part of a cost-cutting effort following its strategic pivot to PDS0301 and a going concern warning.
Key Events · Executive and Board Changes · PDSB
-
36% Workforce Reduction
Board approved a reduction in force on August 6, 2026, affecting approximately 36% of employees, with notifications delivered August 21, 2026 and completion expected in Q3 2026.
-
COO Terminated Without Cause
Stephan Toutain was removed as Chief Operating Officer effective August 21, 2026, and will receive 12 months base salary plus 12 months COBRA contributions under his employment agreement.
-
$842K Severance Charge
The company estimates a one-time Q3 2026 charge of approximately $842,000 for employee separation benefits, all expected to be cash expenditures.
-
Strategic Refocus Context
The restructuring follows the August 11, 2026 announcement discontinuing the PDS0101 Phase 3 VERSATILE-003 trial and redirecting resources to PDS0301.
Analysis · PDSB · Life Sciences
PDS Biotech is cutting roughly 36% of its workforce and has terminated its Chief Operating Officer without cause, both effective August 21, 2026. The layoffs will cost about $842,000 in severance in Q3 2026. This comes just ten days after the company announced it was discontinuing its lead Phase 3 trial and pivoting to PDS0301, and two weeks after its 10-Q revealed only $5.6 million in cash and a going concern warning. The restructuring is a direct response to that cash crunch — shrinking the organization to extend runway while it seeks a partner for PDS0101 and advances PDS0301.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.